Automated Multiplex CRISPR-Cas12j (CasPhi) Vector Foundry Cap Rate 2026

Underwrite GMP Class A/B continuous synthetic ultra-compact Cas12j (CasPhi, 700 amino acid bacteriophage nuclease) all-in-one non-viral and AAV vector suites, $590/sqft base lease rates, and exit cap rates.

Underwriting Assumptions

CasPhi Cleanroom Footprint (sqft)

NNN Base Lease Rate ($/sqft/yr)

Turnkey GMP CasPhi Foundry Acquisition ($)

Target Exit Capitalization Rate (%)

Projected Economics

Net Operating Income (NOI)

Going-In Capitalization Rate

Stabilized Institutional Valuation